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Chem. '262, 12059-I2076 Fukuda. M Fukuda, M., Spooncer, E., Oates, J. E., Dell, A. Arterial smooth muscle cells synthesize both iri vivo and in vitro three types of sulphated proteoglycans: proteochondroitin sulphate, proteodermatan sulphate and proteoheparan sulphate, and distribute them preferably to the extracellular and cell-surface associated compartment. The proteoglycan-protein interaction of the dermatan-sulphaterich proteoglycan (DS-PG) and heparan sulphate proteoglycan (HS-PG) has been studied in more detail. The DS-PG synthesized by arterial smooth muscle cells belongs to the group of small proteoglycans. It has a molecular mass of about 180000 and contains six to seven dermatan-sulphate-rich side-chains. The ['sS]methioninelabelled protein core has a molecular mass of about 48 000 (Schmidt & Buddecke, 1985 , 1987 . About 70% of DS-PG synthesized by the cells is released into the culture medium. In bovine and human arterial tissue the extracellular DS-PG is associated with collagen fibrils. After specific staining of DS-PG with Cuprolinic Blue, the DS-PG can be visualized in electron micrographs as proteoglycan/Cuprolinic Blue precipitate linked to adjacent collagen fibrils at the periodically spaced d-band regions of collagen. The protein core of DS-PG is probably responsible for the binding to collagen fibrils. If the glycosaminoglycan side-chains, which are highly negatively charged, were responsible one would expect an electrostatic binding, but the d-band where the DS-PG is located, is not positively charged. Therefore, electrostatic binding of DS-PG to the collagen fibril is unlikely.
In the course of the catabolic pathway the DS-PG is released from collagen and internalized from the extracelMar compartment by endocytosis. Endocytosis was found to be a specific and saturable process involving specific interaction of DS-PG to cell surface receptors (Schmidt & Buddecke, 1985) . Uptake of DS-PG shows saturable kinetics. At saturation one cell may endocytose up to 1.5 x lo6 * Abbreviations used: DS-PG, dermatan-sulphate-rich proteoglycan; HS-PG, heparan sulphate proteoglycan.
DS-PG molecules/h. Endocytosis of DS-PG may be inhibited competitively by non-labelled DS-PG isolated from cell cultures or from bovine aorta. A Ki value of 18.3 nmol/ml was calculated in the presence of 85 nmol of non-labelled DS-PG/ml. No inhibition of endocytosis of DS-PG was observed in the presence of a 5-fold excess of non-labelled chondroitin-sulphate-rich proteoglycan isolated from cell cultures or bovine aorta. The latter is also internalized by arterial smooth muscle cells, but at a 10-fold lower rate. The slow uptake of "S-labelled chondroitin-sulphate-rich proteoglycan was not influenced by non-labelled DS-PG thus indicating that DS-PG and the chondroitin-sulphate-rich PG do not compete for the same binding site. Free chondroitin sulphate and dermatan sulphate chains, up to a concentration of 1.6 mmol/ml, did not inhibit endocytosis nor were these polysaccharides endocytosed when presented to the cells as [3sSS]glycosaminoglycans. From these data it is concluded that the protein core of DS-PG interacts with a DS-PG-specific cell surface receptor as the initial step for endocytosis.
Using proteoglycan-gold conjugates, which appear in electron micrographs as pearl-string-like gold strands of about 170 nm length, binding, endocytosis and intracellular translocation of DS-PG can be visualized (Volker er al., 1984) . The proteoglycan-gold conjugates bind to coated as well as to non-coated cell surface membrane areas at 4°C. Post-incubation at 37°C leads to a time-dependent uptake of DS-PG via non-coated and coated vesicles, which after fusion are translocated to multi-vesicle bodies and to largesized vesicles within 1 h. After conversion of these vesicles to lysosomal compartments, the gold particles are uncoupled from the proteoglycan and are concentrated within residual vacuoles.
The recognition site of DS-PG required for interaction with the cell-surface receptor depends on the presence of a recognition marker which resides in the protein core of DS-PG and involves lysine residues (Glossl et al., 1983) nature of DS-PG and its self-aggregation tendency, did not allow the calculation of the number of high-affinity binding sites. However, when the DS chains of DS-PG are degraded by chondroitin ABC lyase, the isolated and '2'l-labelled protein core binds to cultured smooth muscle cells at 4°C in a saturable manner. From Scatchard plots 4.2 x 1 0' binding sites per cell/ were calculated.
To characterize a DS-PG core protein-binding cell-surface protein, cultured arterial smooth muscle cells were labelled with [ 35S]methionine. The cell membranes were then isolated by standard methods, solubilized and submitted to affinity chromatography using a Scpharose-bound core protein of DS-PG. The fraction eluted from the affinity column gave radioactivity bands at M, 61000 and 44000 (double band) on SDS electrophoresis (Fig. 1 ) .
In independent experiments the interaction of HS-PG of arterial wall and arterial smooth muscle cell proteins was studied. HS-PG was isolated from bovine arterial tissue and cultured arterial smooth musclc cells. "S-Labelling experiments show that the bulk of HS-PG synthesized by arterial smooth muscle cells within 48 h resides in the cell layer. It was characterized as a proteoglycan with an apparent M, of 200000 consisting of a protein core ( M , 91 000) to which thrcc to four heparan sulphatc sidc-chains are covalently linked. Pulse-chase experiments rcvealed that about 40% of the cell-layer-associated HS-PG is released into the medium and that the remainder is internalized and converted to smaller species.
In native arterial tissue the extracellular HS-PG is shown by electron microscopy to be associated mainly with the external surface of elastic fibres (Volker et al., 1986) and identified by its susceptibility to heparan-sulphate-degrading enzymes. Since under conditions in vivo the majority of HS-PG is located extracellularly, it was isolated from bovine arterial tissue by sequential collagenase and elastase digestion in the presence of proteinase inhibitors. The HS-PG of arterial tissue has an M, 175000 and possesses four heparan sulphate side-chains ( M , 32 000) covalently bound to the protein core via a galactose-and xylose-containing polysaccharide protein-binding region. The protein core of the arterial tissue HS-PG was found to be significantly smaller (M, 38000) than that of the cell-membraneintegrated HS-PG of cultured arterial smooth muscle cclls.
Extracellular HS-PG is endocytosed by arterial smooth muscle cells via saturable kinetics, but in contrast to DS-PG, the heparan sulphate side-chains (and not the protein core) bind to a specific cell-surface protein (Krugcr & Kresse, 1986) .
A special interest in the HS-PG of artcrial smooth musclc cells has been stimulated by the report of Fritze et al. (1985) that post-confluent arterial smooth muscle cells produce a cell-surface heparan-sulphate species with antiprolifcrative activity. We have confirmed this observation and found that the cell-surface heparan sulphate, but not the cell-surface chondroitin sulphate, and dermatan sulphate have an antiproliferative activity significantly higher than that of cquivalent amounts of heparin. Moreover, in contrast to heparin, the antiproliferative heparan sulphate preparation had no antithrombogenic effect, which was tested by the ability of heparin and heparan sulphate to prevcnt the conversion of prothrombin to thrombin. From these data it is concluded that there are different structural requiremcnts for the antiproliferative and antithrombogenic function of heparan sulphate and heparin, respectively. The antiproliferative activity of the heparan sulphate side-chains of HS-PG suggests that bovine arterial smooth muscle cells are capable of controlling their own growth and raises the question of the structural determinants of the antiproliferative domain of heparan sulphate.
